Latest Revalesio News & Updates

See the latest news and media coverage for Revalesio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Revalesio

Clinical-stage developer of mitochondrial therapies for neurological and age-related diseases

revalesio.com

Headquarters: Tacoma, United States
Company type: Private company
Number of employees: 21–50
Industry: Pharmaceuticals

Last updated April 16

Latest news about Revalesio

In short: Revalesio reported positive RNS60 stroke and ALS trial results and secured FDA Fast Track designation.

Company announcements

April 16 Revalesio

Revalesio shares RNS60's positive stroke outcomes

A study in Stroke: Vascular Interventional Neurology shows patients receiving high-dose RNS60 with EVT had shorter hospital stays than EVT alone.

March 5 Revalesio

Revalesio presents stroke treatment advances with RNS60 at ASENT meeting

Acting CMO Jordan Dubow showcases Phase 2 RESCUE trial data on infarct reduction and outcomes. VP Andreas Kalmas presents post hoc analysis showing shorter hospital stays and higher home discharges.

October 23, 2025 Revalesio

Revalesio prepares for Phase 3 trial launch

World Stroke Congress features RNS60 as potential stroke treatment option.

February 7, 2024 Revalesio

Revalesio announces positive Phase 2 RESCUE study data for RNS60

RNS60 met safety and mortality endpoints, reduced infarct growth by 50%, showed functional improvements, and plans FDA meeting for Phase 3.

Media coverage

March 5 BioSpace

Revalesio to Present Advances in Stroke Treatment with RNS60 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting - BioSpace

TACOMA, Wash., March 5, 2026 /PRNewswire/ -- Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced its participation in...

July 14, 2025 KXAN

Revalesio to Present Phase 3 Trial Design and Post Hoc Analysis of Phase 2 RESCUE Trial of RNS60 in Acute Ischemic Stroke at the SNIS 22nd Annual Meeting

TACOMA, Wash., July 14, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that two abstracts...

October 9, 2024 WBOY

Revalesio's Investigational Treatment RNS60 Protects Mitochondria in Preclinical Model of Amyotrophic Lateral Sclerosis (ALS)

TACOMA, Wash., Oct. 9, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced new data showing...

February 7, 2024 Koin

REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION ...

TACOMA, Wash., Feb. 7, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, announced today topline data from...

Never miss news about Revalesio

Track Revalesio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Revalesio competitors & trending companies

Browse news for competitors to Revalesio and other trending companies.